Comparative Effectiveness of Empiric Antibiotics for Community-Acquired Pneumonia

被引:37
|
作者
Queen, Mary Ann [1 ]
Myers, Angela L. [2 ,3 ]
Hall, Matthew [4 ]
Shah, Samir S. [5 ]
Williams, Derek J. [7 ]
Auger, Katherine A. [6 ]
Jerardi, Karen E. [6 ]
Statile, Angela M. [6 ]
Tieder, Joel S. [8 ]
机构
[1] Childrens Mercy Hosp & Clin, Div Hosp Med, Kansas City, MO 64108 USA
[2] Childrens Mercy Hosp & Clin, Div Infect Dis, Kansas City, MO 64108 USA
[3] Univ Missouri, Sch Med, Kansas City, MO 64108 USA
[4] Childrens Hosp Assoc, Overland Pk, KS USA
[5] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Infect Dis, Cincinnati, OH USA
[6] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Hosp Med, Cincinnati, OH USA
[7] Vanderbilt Univ, Sch Med, Monroe Carell Jr Childrens Hosp Vanderbilt, Div Hosp Med, Nashville, TN 37212 USA
[8] Univ Washington, Sch Med, Seattle Childrens Hosp, Div Hosp Med, Seattle, WA USA
关键词
pneumonia; pediatric; antibiotics; comparative effectiveness; hospitalized; ORAL BETA-LACTAMS; IN-VITRO; CHILDREN; PENICILLIN; VIVO; CARE;
D O I
10.1542/peds.2013-1773
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
BACKGROUND AND OBJECTIVE: Narrow-spectrum antibiotics are recommended as the first-line agent for children hospitalized with community-acquired pneumonia (CAP). There is little scientific evidence to support that this consensus-based recommendation is as effective as the more commonly used broad-spectrum antibiotics. The objective was to compare the effectiveness of empiric treatment with narrow-spectrum therapy versus broad-spectrum therapy for children hospitalized with uncomplicated CAP. METHODS: This multicenter retrospective cohort study using medical records included children aged 2 months to 18 years at 4 children's hospitals in 2010 with a discharge diagnosis of CAP. Patients receiving either narrow-spectrum or broad-spectrum therapy in the first 2 days of hospitalization were eligible. Patients were matched by using propensity scores that determined each patient's likelihood of receiving empiric narrow or broad coverage. A multivariate logistic regression analysis evaluated the relationship between antibiotic and hospital length of stay (LOS), 7-day readmission, standardized daily costs, duration of fever, and duration of supplemental oxygen. RESULTS: Among 492 patients, 52% were empirically treated with a narrow-spectrum agent and 48% with a broad-spectrum agent. In the adjusted analysis, the narrow-spectrum group had a 10-hour shorter LOS (P = .04). There was no significant difference in duration of oxygen, duration of fever, or readmission. When modeled for LOS, there was no difference in average daily standardized cost (P = .62) or average daily standardized pharmacy cost (P = .26). CONCLUSIONS: Compared with broad-spectrum agents, narrow-spectrum antibiotic coverage is associated with similar outcomes. Our findings support national consensus recommendations for the use of narrow-spectrum antibiotics in children hospitalized with CAP.
引用
收藏
页码:E23 / E29
页数:7
相关论文
共 50 条
  • [1] The effectiveness of new antibiotics in the treatment of community-acquired pneumonia
    Trzcina, Nikodem
    Wieczfinska, Joanna
    Pawliczak, Rafal
    ALERGOLOGIA POLSKA-POLISH JOURNAL OF ALLERGOLOGY, 2023, 10 (02) : 112 - 117
  • [2] Aspiration risks factors, microbiology and empiric antibiotics for patients hospitalized with community-acquired pneumonia
    Marin Corral, Judith
    Pascual Guardia, Sergi
    Amati, Francesco
    Aliberti, Stefano
    Ramon Masclans, Joan
    Soni, Nilam
    Rodriguez, Alejandro
    Sbila, Oriol
    Sanz, Francisco
    Sotgiu, Giovanni
    Anzueto, Antonio
    Dimakou, Katerina
    Medenica, Miras
    Petrino, Roberta
    Van de Garde, Ewoudt
    Restrepo, Marcos, I
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [3] Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired Pneumonia
    Marin-Corral, Judith
    Pascual-Guardia, Sergi
    Amati, Francesco
    Aliberti, Stefano
    Masclans, Joan R.
    Soni, Nilam
    Rodriguez, Alejandro
    Sibila, Oriol
    Sanz, Francisco
    Sotgiu, Giovanni
    Anzueto, Antonio
    Dimakou, Katerina
    Petrino, Roberta
    van de Garde, Ewoudt
    Restrepo, Marcos I.
    CHEST, 2021, 159 (01) : 58 - 72
  • [4] Antibiotics for community-acquired pneumonia in children
    Lodha, Rakesh
    Kabra, Sushil K.
    Pandey, Ravindra M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (06):
  • [5] Antibiotics for community-acquired pneumonia in children
    Kabra, Sushil K.
    Lodha, Rakesh
    Pandey, Ravindra M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (03):
  • [6] New antibiotics for community-acquired pneumonia
    Kollef, Marin H.
    Betthauser, Kevin D.
    CURRENT OPINION IN INFECTIOUS DISEASES, 2019, 32 (02) : 169 - 175
  • [7] Emerging antibiotics for community-acquired pneumonia
    Liapikou, Adamantia
    Cilloniz, Catia
    Palomeque, Andrea
    Torres, Toni
    EXPERT OPINION ON EMERGING DRUGS, 2019, 24 (04) : 221 - 231
  • [8] Empiric antibiotic therapy in children with community-acquired pneumonia
    Zhang, Linjie
    Lovatel, Raquel
    Nicolete, Dilvania
    Sinzkel, Etienne
    Matiello, Juliana
    Staszko, Kamil
    Lincho, Carla
    INDIAN PEDIATRICS, 2008, 45 (07) : 554 - 558
  • [9] Comparative Effectiveness of Ceftriaxone in Combination With a Macrolide Compared With Ceftriaxone Alone for Pediatric Patients Hospitalized With Community-acquired Pneumonia
    Leyenaar, JoAnna K.
    Shieh, Meng-Shiou
    Lagu, Tara
    Pekow, Penelope S.
    Lindenauer, Peter K.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2014, 33 (04) : 387 - 392
  • [10] Antibiotics for community-acquired pneumonia: Only sometimes!
    Weinberger, Miles
    PEDIATRIC PULMONOLOGY, 2019, 54 (08) : 1106 - 1107